Table 1. Correlations between CCBE1 expression and clinicopathologic features in patients with gastrointestinal stromal tumor (GIST).

Clinicopathological feature		Total 325	Expression of CCBE1
			Low (n = 164, 54.3%)	High (n = 161, 45.7%)	P value (χ2 test)
Age (years)	≤59	169	87 (51.5)	82 (48.5)	0.702
	>59	156	77 (49.4)	79 (50.6)
Gender	Male	174	85 (48.9)	89 (51.1)	0.533
	Female	151	79 (52.3)	72 (47.7)
Modified NIH criteria	Low risk	138	88 (63.8)	50 (36.2)	<0.001
	Intermediate risk	48	28 (58.3)	20 (41.7)
	High risk	139	48 (34.5)	91 (65.5)
Tumor size	≤2 cm	30	25 (83.3)	5 (16.7)	<0.001
	2–5 cm	120	71 (59.2)	49 (40.8)
	5–10 cm	117	52 (44.4)	65 (55.6)
	≥10 cm	58	16 (27.6)	42 (72.4)
Tumor site	stomach	174	94 (54.0)	80 (46.0)	0.012
	Small bowel	107	44 (41.1)	63 (58.9)
	colon	16	13 (81.3)	3 (18.7)
	others	28	13 (46.4)	15 (53.6)
Mitoses per 50 HPFs	≤5	238	132 (55.5)	106 (44.5)	0.008
	5–10	46	19 (41.3)	27 (58.7)
	≥10	41	13 (31.7)	28 (68.3)
Tumor bleeding	yes	53	26 (49.1)	27 (50.9)	0.823
	no	272	138 (50.7)	134 (49.3)
Ki67 classification	I	240	133 (55.4)	107 (44.6)	0.005
	II	41	18 (43.9)	23 (56.1)
	III	44	13 (29.5)	31 (70.5)
Recurrence	truncation	264	145 (54.9)	119 (45.1)	0.001
	recurrent	61	19 (31.1)	42 (68.9)
NIH invasion	1	26	21 (80.8)	5 (19.2)	<0.001
	2	112	67 (59.8)	45 (40.2)
	3	48	28 (58.3)	20 (41.7)
	4	88	29 (33.0)	59 (67.0)
	5	51	19 (37.3)	32 (62.7)

Abbreviations: HPF, high power field of the microscope; NIH, National Institutes of Health.

*Median age of total 325 patients was 59 years.

Values in parentheses indicate percentage values. The bold number represents the P–values with significant differences calculated by χ² test.